Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Frontier Clinical Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$4,773,964

714 payments

Through program year 2025, Frontier Clinical Research, LLC is reported as receiving $4,773,964 in research payments, across 714 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,777,194 421
2024 Research $1,156,241 113
2023 Research $1,012,339 78
2022 Research $328,619 16
2021 Research $102,499 46
2020 Research $8,851 4
2019 Research $388,220 36

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,289,171 83 payments
  2. Genentech, Inc. $790,545 77 payments
  3. Novartis Pharmaceuticals Corporation $597,108 6 payments
  4. Ipsen Innovation $359,470 327 payments
  5. AbbVie, Inc. $290,635 27 payments
  6. Bausch Health US, LLC $187,230 143 payments
  7. Abbott Laboratories $86,900 6 payments
  8. Moderna TX, Inc. $72,829 5 payments
  9. AstraZeneca UK Limited $53,362 2 payments
  10. Boehringer Ingelheim Canada Ltd.Ltee $21,548 29 payments
Studies the money was for Research payments · program years 2019–2025
  1. Transmission Study Household $790,545 77 payments
  2. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $512,637 38 payments
  3. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $492,989 3 payments
  4. A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) $491,071 3 payments
  5. A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus $358,029 2 payments
  6. M16-100 $272,700 25 payments
  7. A Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA) $245,645 6 payments
  8. A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants $243,944 220 payments
  9. Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) $187,230 143 payments
  10. A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event $148,723 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record